title: Direct thrombin inhibitors.
abstract: Bivalent direct thrombin inhibitors reduce ischemic risk compared to heparin. Results from randomized, double-blind clinical trials have demonstrated that bivalirudin is superior to heparin alone and as effective as heparin plus routine glycoprotein (GP) IIb/IIIa therapy for the prevention of ischemic events with a statistically significant reduction in the rate of in-hospital major bleeding.
authors.affiliation: Sanger Clinic, 1001 Blythe Blvd., #300, Charlotte, NC 28203, USA. csimonton@sanger-clinic.com
authors.forename: Charles
authors.initials: C
authors.lastname: Simonton
mesh_terms: D054058:Acute Coronary Syndrome / Q000188:drug therapy*; D015906:Angioplasty, Balloon, Coronary; D000991:Antithrombins / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000401:mortality / Q000628:therapy*; D003365:Costs and Cost Analysis; D003925:Diabetic Angiopathies / Q000628:therapy; D006629:Hirudins / Q000191:economics / Q000493:pharmacokinetics; D006801:Humans; D010446:Peptide Fragments / Q000191:economics / Q000493:pharmacokinetics / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000191:economics / Q000493:pharmacokinetics / Q000627:therapeutic use; D018570:Risk Assessment; D016896:Treatment Outcome
chemical_list: D000991:Antithrombins; D006629:Hirudins; D010446:Peptide Fragments; D011994:Recombinant Proteins; C074619:bivalirudin